Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05926011 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy of RGn600 in Patients With Mild-to-moderate Alzheimer's Disease

Study acronym: LIGHT4LIFE
StatusRecruiting
PhaseNot applicable
Started2023-07-24
View on ClinicalTrials.gov ↗
This is a controlled investigation, with randomization of the patients, which aims at demonstrating the efficacy of device RGn600 in treating patients with mild-to-moderate Alzheimer's disease (AD). RGn600 is a non-invasive medical device which is applied on the head (helmet) and on the abdomen (abdominal belt). It combines 2 technologies: * PhotoBioModulation (PBM), which involves exposure to light from the red to near-infrared wavelengths using lasers and Light Emitting Diodes (LEDs) * Static Magnetic Stimulation (SMS), which consists in the application of a static magnetic field. Considering previous investigations, this innovative technology could reduce inflammation on the brain-gut axis, implicated in the development of Alzheimer's disease.

Amendment history 2 changes detected by DataLookout

2026-08-11
critical
Primary completion pushed: 2026-06 → 2027-06
2026-08-11
minor
Completion pushed: 2026-12 → 2027-12
Trial Details
NCT Number NCT05926011
Lead Sponsor REGEnLIFE SAS
Collaborators: RCTs, University Hospital, Toulouse
Conditions Alzheimer Disease
Enrollment 108 participants
Start Date 2023-07-24
Primary Completion 2027-06 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-21